Published in Int J Radiat Oncol Biol Phys on February 03, 2010
Stereotactic Radiosurgery for Brainstem Metastases: An International Cooperative Study to Define Response and Toxicity. Int J Radiat Oncol Biol Phys (2016) 1.40
Local control and toxicity outcomes in brainstem metastases treated with single fraction radiosurgery: is there a volume threshold for toxicity? J Neurooncol (2014) 0.98
Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer (2012) 0.91
Gamma knife treatment of brainstem metastases. Int J Mol Sci (2014) 0.85
A review of the clinical outcomes for patients diagnosed with brainstem metastasis and treated with stereotactic radiosurgery. ISRN Surg (2013) 0.83
Gamma knife stereotactic radiosurgery in the treatment of brainstem metastases: The MD Anderson experience. Neurooncol Pract (2015) 0.80
Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases. Radiat Oncol (2012) 0.79
Gamma knife radiosurgery treatment for metastatic melanoma of the trigeminal nerve and brainstem: a case report and a review of the literature. Case Rep Neurol Med (2013) 0.78
Stereotactic aspiration combined with gamma knife radiosurgery for the treatment of cystic brainstem metastasis originating from lung adenosquamous carcinoma: A case report. Oncol Lett (2015) 0.77
Long-Term Survival of a Patient with Brainstem and Recurrent Brain Metastasis from Stage IV Nonsmall Cell Lung Cancer Treated with Multiple Gamma Knife Radiosurgeries and Craniotomies: A Case Report and Review of the Literature. Case Rep Oncol Med (2012) 0.77
Radiosurgery for brainstem metastases with and without whole brain radiotherapy: clinical series and literature review. J Radiat Oncol (2016) 0.75
Adaptive hypofractionated gamma knife radiosurgery for a large brainstem metastasis. Surg Neurol Int (2016) 0.75
Long-term outcome of gamma knife radiosurgery for metastatic brain tumors originating from lung cancer. Surg Neurol Int (2014) 0.75
Outcomes and predictors of improved survival after gamma knife radiosurgery for metastatic brain tumors originated from breast carcinoma. Neurosurg Rev (2015) 0.75
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys (2009) 6.11
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst (2005) 4.51
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol (2011) 4.12
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol (2002) 3.06
Seizure-promoting effect of blood-brain barrier disruption. Epilepsia (2007) 3.00
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 2.69
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res (2007) 2.66
Cortical surface registration for image-guided neurosurgery using laser-range scanning. IEEE Trans Med Imaging (2003) 2.47
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 2.41
Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res (2004) 2.41
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature (2004) 2.22
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol (2009) 2.13
Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis (2008) 2.11
A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys (2002) 2.09
Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res (2005) 2.06
The importance of the conformality, heterogeneity, and gradient indices in evaluating Gamma Knife radiosurgery treatment plans for intracranial meningiomas. Int J Radiat Oncol Biol Phys (2011) 2.03
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys (2013) 2.02
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys (2002) 2.01
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol (2013) 1.88
Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol (2009) 1.87
Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol (2014) 1.77
A method to track cortical surface deformations using a laser range scanner. IEEE Trans Med Imaging (2005) 1.75
Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys (2011) 1.74
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg (2013) 1.73
Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.71
Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg (2011) 1.70
Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem (2007) 1.66
Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg (2010) 1.65
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys (2004) 1.64
Modern outcomes of inflammatory breast cancer. Int J Radiat Oncol Biol Phys (2012) 1.63
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology (2010) 1.53
Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg (2012) 1.53
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery (2002) 1.50
Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer (2003) 1.50
Treatment of heterotopic ossification. Orthopedics (2007) 1.49
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol (2009) 1.48
A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res (2004) 1.48
Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases. Expert Rev Neurother (2005) 1.47
Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. J Neurosurg (2006) 1.47
Dural lesions mimicking meningiomas. Hum Pathol (2002) 1.45
Absence of an association between glucose levels and surgical site infections in patients undergoing craniotomies for brain tumors. J Neurosurg (2010) 1.43
Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. Urology (2012) 1.42
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
Severe transient hypertension after greater palatine foramen block in a patient taking midodrine. Am J Otolaryngol (2009) 1.40
Postoperative single-fraction radiation for prevention of heterotopic ossification of the elbow. Int J Radiat Oncol Biol Phys (2010) 1.40
Difficulties with the neurological assessment of humans following a chimpanzee attack. J Neurosurg (2011) 1.39
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res (2009) 1.36
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol (2009) 1.35
Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys (2005) 1.32
A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol (2012) 1.32
Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys (2002) 1.28
Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys (2011) 1.25
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.24
Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg (2003) 1.23
PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys (2005) 1.23
A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol (2009) 1.22
Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol (2007) 1.22
Novel drug delivery strategies in neuro-oncology. Neurotherapeutics (2009) 1.21
Spine metastases: current treatments and future directions. Eur J Cancer (2010) 1.21
Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys (2012) 1.20
Brain metastases of breast cancer. Breast Dis (2007) 1.20
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.19
Intraoperative optical spectroscopy identifies infiltrating glioma margins with high sensitivity. Neurosurgery (2005) 1.18
Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene (2004) 1.18
N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle (2007) 1.17
Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol (2011) 1.17